Not yet recruitingPHASE1, PHASE2NCT07371793

A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis

Studying Hereditary Hemochromatosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Bond Biosciences
Principal Investigator: Curtis Scribner, MD, LCSW
Bond Biosciences
Intervention: BBI-001(drug)
Enrollment: 34 enrolled
Eligibility: 18-70 years · All sexes
Timeline: 2026 – 2027

Study locations (1)

Clinical Research Unit, Sydney, New South Wales, Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07371793 on ClinicalTrials.gov

← Back to all trials